Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. Assaf ZJF, et al. Among authors: fabrizio d. Nat Med. 2023 Apr;29(4):859-868. doi: 10.1038/s41591-023-02226-6. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928816 Free PMC article.
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. Gandara DR, et al. Among authors: fabrizio d. Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6. Nat Med. 2018. PMID: 30082870
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, Chae YK, Leal TA, Dowell JE, Tsai ML, Dakhil CSR, Stella P, Jin Y, Shames DS, Schleifman E, Fabrizio DA, Phan S, Socinski MA. Kim ES, et al. Nat Med. 2022 May;28(5):939-945. doi: 10.1038/s41591-022-01754-x. Epub 2022 Apr 14. Nat Med. 2022. PMID: 35422531 Free PMC article. Clinical Trial.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Peters S, et al. Among authors: fabrizio da. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. Nat Med. 2022. PMID: 35995953 Free PMC article. Clinical Trial.
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, Ross JS, Frampton GM, Napalkov P, Montesion M, Schutzman JL, Ye X, Hegde PS, Nagasaka M, Oxnard GR, Sokol ES, Ou SI, Shi Z. Lee JK, et al. Among authors: fabrizio d. NPJ Precis Oncol. 2022 Dec 9;6(1):91. doi: 10.1038/s41698-022-00334-z. NPJ Precis Oncol. 2022. PMID: 36494601 Free PMC article.
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Moore JA, Chen KT, Madison R, Newberg JY, Fleischmann Z, Wang S, Sharaf R, Murugesan K, Fendler BJ, Hughes J, Schrock AB, Hegde PS, Oxnard GR, Fabrizio D, Frampton GM, Antonarakis ES, Sokol ES, Jin DX. Moore JA, et al. Among authors: fabrizio d. JCO Precis Oncol. 2023 Sep;7:e2300093. doi: 10.1200/PO.23.00093. JCO Precis Oncol. 2023. PMID: 37769224
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, Tukachinsky H, Pratt J, Fusaro G, Oxnard GR, Green G, Fabrizio D, Baden J. He J, et al. Among authors: fabrizio d. J Immunother Cancer. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339. J Immunother Cancer. 2023. PMID: 38035725 Free PMC article. Clinical Trial.
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.
Sweeney CJ, Petry R, Xu C, Childress M, He J, Fabrizio D, Gjoerup O, Morley S, Catlett T, Assaf ZJ, Yuen K, Wongchenko M, Shah K, Gupta P, Hegde P, Pasquina LW, Mariathasan S, Graf RP, Powles T. Sweeney CJ, et al. Among authors: fabrizio d. Clin Cancer Res. 2024 Sep 13;30(18):4115-4122. doi: 10.1158/1078-0432.CCR-24-1096. Clin Cancer Res. 2024. PMID: 38990098 Free PMC article. Clinical Trial.
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM. Chalmers ZR, et al. Among authors: fabrizio d. Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2. Genome Med. 2017. PMID: 28420421 Free PMC article.
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ. Fabrizio DA, et al. J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06. J Gastrointest Oncol. 2018. PMID: 30151257 Free PMC article.
91 results